Investigation of the Relationship Between the Level Of Serum Apelin and Nesfatin-1 in Patients with Treatment of Depression

2017-01-02T19-12-35Z
Source: Düşünen Adam: The Journal of Psychiatry and Neurological Sciences
Şahap Dede, Musa Şahpolat, Mehmet Hanifi Kokaçya, Mustafa Arı, Cem Sesliokuyucu, Zafer Yönden.
Objective: This study was designed to investigate the relationship of the before and after treatment of the new discovered molecules apelin and nesfatin-1 and to investigate of it can be used as a biomarker. Method: This research has been done with 47 patients of depression without treatment and 47 normal healthy volunteers who admitted to a psychiatric polyclinic. All participants were performed with structured Clinical Interview for DSM-IV (SCID-I), Hamilton Depression Rating Scale, Clinical Global Impression Scale. Before and 3 months after the beginning of treatment peripheral blood samples were taken after 12 hours of fasting. Results: From the 47 depression patients 35 (74.5%) were female and 12 (25.5%) were male. For the 47 volunteers 31 (66%) were female and 16 (34%) were male. There was no difference between groups in terms of age, marital status, occupation, and Body Mass Index (BMI). Plasma apelin levels were significantly higher in patient group than control group. No statistically significant difference was found in plasma nesfatin-1 levels between the patient group and the control group. After 3 months of treatment there was no statistically significant difference in both apelin and nesfatin-1 levels. Conclusions: According to the study findings application of the plasma apelin levels were significantly higher than instant healthy controls and after a 3-month treatment of depression despite clinical improvement there was no significant changes in the level of plasma apelin. The plasma nesfatin-1 levels of the group of patients were not different during the application and after 3 months of treatment. In our study, there was no correlation between BMI and the level of plasma apelin. Between the plasma nesfatin-1 level of the the admission and the BMI which is measured during the application a correlation is detected.


from Scope via xlomafota13 on Inoreader http://ift.tt/2hLVCoC
via IFTTT